LNTH Insider Trading

Insider Ownership Percentage: 1.50%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $12,590,187.37

Lantheus Insider Trading History Chart

This chart shows the insider buying and selling history at Lantheus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$6.11MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$40M-$20M$0$20M$40MTotal Insider BuyingTotal Insider Selling

Lantheus Share Price & Price History

Current Price: $96.16
Price Change: Price Decrease of -0.88 (-0.91%)
As of 03/28/2025 05:00 PM ET

This chart shows the closing price history over time for LNTH up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$96.16Closing price on 03/28/25:

SEC Filings (Institutional Ownership Changes) for Lantheus (NASDAQ:LNTH)

99.06% of Lantheus stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at LNTH by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$1.07Bbought$320MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1B-$500M$0$500M$1BTotal InflowsTotal Outflows
Lantheus logo
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Read More on Lantheus

Today's Range

Now: $96.16
Low: $94.75
High: $97.39

50 Day Range

MA: $93.21
Low: $78.23
High: $110.01

52 Week Range

Now: $96.16
Low: $58.16
High: $126.89

Volume

617,660 shs

Average Volume

942,021 shs

Market Capitalization

$6.59 billion

P/E Ratio

16.00

Dividend Yield

N/A

Beta

0.38

Who are the company insiders with the largest holdings of Lantheus?

Lantheus' top insider investors include:
  1. Lantheus Alpha Therapy, Llc (Major Shareholder)
  2. Mary Anne Heino (Director)
  3. Mary Anne Heino (CEO)
  4. Robert J Jr Marshall (CFO)
  5. Paul Blanchfield (President)
  6. Daniel Niedzwiecki (Insider)
  7. Etienne Montagut (Insider)
  8. Andrea Sabens (CAO)
  9. James H Thrall (Director)
  10. Heinz Christoph Maeusli (Director)
  11. Gerard Ber (Director)
  12. Gary J Pruden (Director)
  13. Minnie Baylor-Henry (Director)
Learn More about top insider investors at Lantheus.

Who are the major institutional investors of Lantheus?

Lantheus' top institutional investors include:
  1. Vanguard Group Inc. — 10.42%
  2. Janus Henderson Group PLC — 8.92%
  3. Farallon Capital Management LLC — 7.65%
  4. Geode Capital Management LLC — 2.42%
  5. T. Rowe Price Investment Management Inc. — 2.17%
  6. Reinhart Partners LLC. — 1.97%
Learn More about top institutional investors of Lantheus stock.

Which major investors are selling Lantheus stock?

In the previous quarter, LNTH stock was sold by these institutional investors:
  1. Hood River Capital Management LLC
  2. Fuller & Thaler Asset Management Inc.
  3. Gilder Gagnon Howe & Co. LLC
  4. Renaissance Technologies LLC
  5. Vanguard Group Inc.
  6. Clearbridge Investments LLC
  7. Marshall Wace LLP
  8. Price T Rowe Associates Inc. MD
In the last year, company insiders that have sold Lantheus company stock include:
  1. Lantheus Alpha Therapy, Llc (Major Shareholder)
  2. Mary Anne Heino (Director)
  3. Mary Anne Heino (CEO)
  4. Robert J Jr Marshall (CFO)
  5. Paul Blanchfield (President)
  6. Daniel Niedzwiecki (Insider)
  7. Etienne Montagut (Insider)
  8. Andrea Sabens (CAO)
  9. James H Thrall (Director)
Learn More investors selling Lantheus stock.

Which major investors are buying Lantheus stock?

In the previous quarter, LNTH stock was acquired by institutional investors including:
  1. Janus Henderson Group PLC
  2. Farallon Capital Management LLC
  3. T. Rowe Price Investment Management Inc.
  4. Raymond James Financial Inc.
  5. Raymond James Financial Inc.
  6. Swedbank AB
  7. Keybank National Association OH
  8. Norges Bank